Table 1.
Major study characteristics from the ten RCTs included in the meta-analysis
Literature | Year | Treated Patients | Placebo | Therapy strategy | Duration of therapy | Jadad Scale |
---|---|---|---|---|---|---|
Suzuki et al9 |
2001 | 55 | 54 | Erythromycin 200–400 mg once daily |
12 months | 2 |
Banerjee et al10 | 2004 | 31 | 36 | Clarithromycin 500 mg once daily |
3 months | 3 |
Seemungal et al11 | 2008 | 53 | 56 | Erythromycin 250 mg twice daily |
12 months | 5 |
He et al12 | 2010 | 18 | 18 | Erythromycin 125 mg three times daily |
6 months | 4 |
Albert et al13 | 2011 | 558 | 559 | Azithromycin 250 mg once daily |
12 months | 3 |
Berkhof et al14 | 2013 | 42 | 42 | Azithromycin 250 mg three times a week |
3 months | 5 |
Uzun et al15 | 2014 | 47 | 45 | Azithromycin 500 mg three days a week |
12 months | 5 |
Simpson et al16 | 2014 | 15 | 15 | Azithromycin 250 mg once daily |
12 months | 5 |
Shafuddin et al17 | 2015 | 97 | 94 | Roxithromycin 300 mg once daily |
3 months | 5 |
Ra et al18 | 2017 | 504 | 499 | Azithromycin 250 mg once daily |
12 months | 4 |
Abbreviation: RCTs, randomized controlled trials.